Searchable abstracts of presentations at key conferences in endocrinology

ea0063oc8.5 | Reproduction 1 | ECE2019

The neurokinin 3 receptor antagonist, fezolinetant, is effective in treatment of menopausal vasomotor symptoms: responder analysis results from a randomized, placebo-controlled, double-blind, dose-ranging study

Fraser Graeme , Lederman Samuel , Waldbaum Arthur , Young James , Skillern Laurence , Ramael Steven

Background: The brain’s thermoregulatory center is stimulated by activation of neurokinin 3 receptor (NK3R) and inhibited by estrogen. In menopause, declining estrogen disturbs this balance, producing vasomotor symptoms (VMS). This study assessed response to the NK3R antagonist fezolinetant in women with menopausal VMS.Methods: This phase 2b, double-blind trial (NCT03192176) randomized menopausal women (age >40−65 y) with moderate/severe V...